Piper Sandler adjusted its stance on Amphastar Pharmaceuticals (NASDAQ:AMPH), downgrading the company's stock rating from Overweight to Neutral and significantly reducing the price target to $36.00 ...

Piper Sandler downgraded Amphastar (AMPH) to Neutral from Overweight with a price target of $36, down from $66. The firm noted that shares of ...

In a report released today, Jason Gerberry from Bank of America Securities reiterated a Hold rating on Amphastar Pharmaceuticals (AMPH – ...

RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Piper Sandler cut shares of Amphastar Pharmaceuticals (NASDAQ:AMPH – Free Report) from an overweight rating to a neutral rating in a research note issued to investors on Tuesday, Marketbeat reports.

RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ever wonder which ETFs do the best job at beating the benchmark index? This list is a good place to start.

View Amphastar Pharmaceuticals, Inc. (AMPH) current and estimated P/E ratio data provided by Seeking Alpha.